106827-26-3

Basic information

• Product Name: 5-(2,3-DICHLOROPHENYL)-2-FURALDEHYDE
• Synonyms: AURORA KA-4239;ASISCHEM N39069;ART-CHEM-BB B025340;AKOS BB-8328;5-(2,3-DICHLOROPHENYL)-2-FURALDEHYDE;5-(2,3-DICHLORO-PHENYL)-FURAN-2-CARBALDEHYDE;VITAS-BB TBB005618;ZERENEX ZX008815
• CAS NO: 106827-26-3
• Molecular Formula: C11H6Cl2O2
• Molecular Weight: 241.07
• Mol File: 106827-26-3.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 366 °C at 760 mmHg
• Flash Point: 175.1 °C
• Appearance: /
• Density: 1.392 g/cm³
• Vapor Pressure: 1.51E-05mmHg at 25°C
• Refractive Index: 1.605
• CAS DataBase Reference: 5-(2,3-DICHLOROPHENYL)-2-FURALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(2,3-DICHLOROPHENYL)-2-FURALDEHYDE(106827-26-3)
• EPA Substance Registry System: 5-(2,3-DICHLOROPHENYL)-2-FURALDEHYDE(106827-26-3)

Safety Data

• Hazardous Substances Data: 106827-26-3(Hazardous Substances Data)

Usage

General Description

5-(2,3-Dichlorophenyl)-2-furaldehyde, also known as DCPF, is a chemical compound with the molecular formula C10H5Cl2O2. It is a yellow crystalline solid that is used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. DCPF is a potent inhibitor of the enzyme poly(ADP-ribose) polymerase (PARP), which is involved in DNA repair. It has been studied for its potential use in cancer treatment, as well as its role in inflammation and neurodegenerative diseases. DCPF has also been identified as a potential environmental pollutant and is a subject of ongoing research to assess its impact on human health and the environment.

InChI:InChI=1/C11H6Cl2O2/c12-9-3-1-2-8(11(9)13)10-5-4-7(6-14)15-10/h1-6H

Upstream product

• 1899-24-7 5-bromo-2-furancarboxaldehyde 

Relevant articles and documents

Discovery of selective protein arginine methyltransferase 5 inhibitors and biological evaluations

Protein arginine methyltransferase 5 (PRMT5) is an important protein arginine methyltransferase that catalyzes the symmetric dimethylation of arginine resides on histones or non-histone substrate proteins. It has been thought as a promising target for many diseases, particularly cancer. Despite the potential applications of PRMT5 inhibitors in cancer treatment, very few of PRMT5i have been publicly reported. In this investigation, virtual screening and structure–activity relationship studies were carried out to discover novel PRMT5i, which finally led to the identification of a number of new PRMT5i. The most active compound, P5i-6, exhibited a considerable inhibitory potency against PRMT5 with an IC50 value of 0.57?μm, and a high selectivity for PRMT5 against other tested PRMTs. It displayed a very good antiviability activity against two colorectal cancer cell lines, HT-29 and DLD-1, and one hepatic cancer cell line, HepG2, in a sensitivity assay against 36 different cancer cell lines. Western blot assays indicated that P5i-6 selectively inhibited the symmetric dimethylations of H4R3 and H3R8 in DLD-1 cells. Overall, P5i-6 could be used as a chemical probe to investigate new functions of PRMT5 in biology and also served as a good lead compound for the development of new PRMT5-targeting therapeutic agents.